Cited by 11Effects of Radiation ExposureHematopoietic Stem Cell TransplantationRadioactive contamination and transfer

Role of molecularly-cloned hematopoietic growth factors after acute high-dose radiation exposures

Open access
Lazarus, Hillard M, Armitage, James O, Gale, Robert Peter·2021·Journal of Radiological Protection

Abstract

Abstract Therapy of acute, high-dose whole-body exposures of humans to ionizing radiations is a complex medical challenge. Since 1944 more than 400 radiologic accidents have been registered with more than 3000 substantial radiation exposures and 127 fatalities. There are several potential interventions including supportive care, transfusions, preventative or therapeutic anti-infection drugs, molecularly-cloned myeloid growth factors and hematopoietic cell transplants. We discuss the use of the granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) to treat acute high-dose ionizing radiation exposures. Considerable data in experimental models including monkeys indicate use of these drugs accelerates bone marrow recovery and in some but not all instances increases survival. In ten accidents since 1996, 30 victims received G-CSF alone or with other growth factors. Twenty-six victims survived. In seven accidents since 1986, 28 victims received GM-CSF alone or with other growth factors; 18 victims survived. However, absent control or data from randomized trials, it is not possible to know with certainty what role, if any, receiving G-CSF or GM-CSF was of benefit. Given the favorable benefit-to-risk ratio of molecularly-cloned myeloid growth factors, their use soon after exposure to acute, high-dose whole-body ionizing radiations is reasonable.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1088/1361-6498/ac0bff

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Both sargramostim and filgrastim have demonstrated a robust safety profile with well-known and minimal side effects including fever, diarrhea, bone pain, and fatigue, making them ideal for use as MCMs.

    “Both drugs have demonstrated a robust safety profile with well-known and minimal side effects in patients including fever, diarrhea, bone pain, and fatigue making them ideal for use as MCMs (Lazarus and Gale, 2021).”

    From Medical countermeasures for the hematopoietic-subsyndrome of acute radiation syndrome in space (2022) · cites this paper as Lazarus and Gale, 2021

    Section 2 identifies filgrastim and sargramostim as FDA-approved treatments for bone marrow recovery after acute high-dose radiation exposure. Section 4 says the interventions seem safe and effective, but cautions that safety data from radiation accidents are difficult to interpret. Our copy does not identify fever, diarrhea, bone pain, or fatigue as their side effects, or establish the robust patient safety profile claimed. (LLM, conf=0.87)

    Experimental — accuracy not yet measured
  • Myeloid colony stimulating factors boost granulopoiesis, differentiation, maturation, and function of hematopoietic progenitor cells to accelerate recovery of blood forming cells in circulation.

    “Myeloid colony stimulating factors boost granulopoiesis, differentiation, maturation, and function of hematopoietic progenitor cells to accelerate recovery of blood forming cells in circulation (Fig. 2) (Lazarus and Gale, 2021).”

    From Medical countermeasures for the hematopoietic-subsyndrome of acute radiation syndrome in space (2022) · cites this paper as Lazarus and Gale, 2021

    Section 2, “Molecularly-cloned myeloid growth factors” (page unavailable), identifies G-CSF and GM-CSF as factors used to accelerate bone marrow recovery after acute high-dose radiation exposure. It does not describe the claimed boosts to granulopoiesis, progenitor-cell differentiation, maturation, or function, or specifically establish faster recovery of circulating blood-forming cells. (LLM, conf=0.83)

    Experimental — accuracy not yet measured
  • In total, between 1996 and 2021, at least thirty patients with ARS have been treated with sargramostim and/or filgrastim.

    “In total, between 1996 and 2021, at least thirty patients with ARS have been treated with sargramostim and/or filgrastim (Lazarus et al., 2021).”

    From Medical countermeasures for the hematopoietic-subsyndrome of acute radiation syndrome in space (2022) · cites this paper as Lazarus et al., 2021

    Section 6 reports 30 accident victims treated with G-CSF between 1996 and 2010, supporting the approximate count within the claimed period. But Table 1 lists PEGylated G-CSF for two of those victims, which Section 2 distinguishes from filgrastim; Section 6 also says exposures were acute or protracted. The paper therefore does not establish that all 30 were patients with ARS treated specifically with sargramostim and/or filgrastim. (LLM, conf=0.84)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

2 retracted

Flagged first, then by citations

1 of the 47 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

  1. Gusev I, Guskova A and Mettler F A (ed) 2001 Medical Management of Radiation Accidents 2nd edn (Boca Raton, FL: CRC Press)

Cited by

Sorted by citations

Authors
Lazarus, H. M., Armitage, J. O., & Gale, R. P.
Affiliations
  • Case Western Reserve University (US)
  • University of Nebraska Medical Center (US)
  • Imperial College London (GB)
Venue
Journal of Radiological Protection
Published
2021-11-10
Volume
41
Issue
4
Pages
S478-S489
ISSN
  • 0952-4746 (ISSN-L)
  • 1361-6498
OpenAlex
W3171717947
Cited by
11
References
47
Citations by year
2026: 3 · 2025: 2 · 2024: 1 · 2022: 3 · 2021: 2
FWCI
0.80
Type
journal article
Language
en
Open access
Locations
  • Journal of Radiological Protection (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute for Health and Care Research
Topics
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Effects of Radiation Exposure
  • Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
  • Physical Sciences › Environmental Science › Global and Planetary Change › Radioactive contamination and transfer
Keywords
radiation accidents, granulocyte colony-stimulating factor, GM-CSF, myeloid growth factors, hematopoietic recovery, bone marrow recovery
MeSH terms
Radiation Exposure, Animals, Bone Marrow, Humans, Radiation, Ionizing, Granulocyte-Macrophage Colony-Stimulating Factor, Granulocyte Colony-Stimulating Factor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review